QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tandem-diabetes-care-achieves-isoiec-270012022-certification-from-insight-assurance

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achie...

 tandem-diabetes-care-announces-that-its-tslim-x2-insulin-pump-with-control-iq-automated-insulin-delivery-now-integrates-with-abbotts-freestyle-libre-3-plus-cgm-in-the-us

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim ...

 dexcom-faces-new-reports-of-deaths-linked-to-g7-glucose-monitor

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

 stifel-reinstates-hold-on-tandem-diabetes-care-announces-15-price-target

Stifel analyst Jonathan Block reinstates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and announces $15 price target.

 truist-securities-maintains-hold-on-tandem-diabetes-care-raises-price-target-to-16

Truist Securities analyst Richard Newitter maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price tar...

 citigroup-maintains-neutral-on-tandem-diabetes-care-raises-price-target-to-15

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target fro...

 canaccord-genuity-maintains-buy-on-tandem-diabetes-care-maintains-24-price-target

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ: TNDM) with a Buy and maintains $24 price ...

 tandem-diabetes-cares-tslim-x2-insulin-pump-with-control-iq-aid-technology-cleared-for-use-with-eli-lillys-lyumjev-ultra-rapid-acting-insulin-in-us

Tandem Diabetes Care, Inc.

 tandem-diabetes-study-finds-automated-insulin-delivery-benefits-adults-with-type-2-diabetes-regardless-of-c-peptide-levels-challenging-current-cms-coverage-criteria

This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and...

 jim-cramer-this-is-the-right-time-to-buy-this-energy-stock

Mad Money's Jim Cramer looks at Phillips 66 and Intuitive Surgical, as well as Tandem Diabetes Care and Cintas.

 oppenheimer-maintains-outperform-on-tandem-diabetes-care-lowers-price-target-to-22

Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price targ...

 citigroup-upgrades-tandem-diabetes-care-to-neutral-raises-price-target-to-1035

Citigroup analyst Joanne Wuensch upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Sell to Neutral and raises the price targe...

 barclays-maintains-overweight-on-tandem-diabetes-care-lowers-price-target-to-51

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from...

 canaccord-genuity-maintains-buy-on-tandem-diabetes-care-lowers-price-target-to-24

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price targ...

 on-aug-6-tandem-diabetes-care-announces-it-received-510k-fda-clearance-for-steadiset

-SEC Filing

 insulet-peer-tandem-diabetes-underwhelming-earnings-dull-outlook-drags-stock

Tandem Diabetes shares fall after a deeper loss, lower guidance, and a device recall tied to 700 adverse events and 59 injuries.

 ubs-maintains-neutral-on-tandem-diabetes-care-lowers-price-target-to-17

UBS analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION